Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

Fan, Liancheng; Wang, Rui; Chi, Chenfei; Cui, Wen; Zhang, Yong; Qian, Hongyang; Shao, Xiaoliang; Wang, Yanqing; Xu, Fan; Pan, Jiahua; Zhu, Yao; Shangguan, Xun; Zhou, Lixin; Dong, Baijun; Xue, Wei

doi:10.1002/pros.23465

Cited by 51 publications

(61 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No available studies were obtained from the Cochrane Library database. A total of 14 studies (11 full-text studies and 3 conference abstracts) were finally included in the present meta-analysis [ 9 , 12 , 13 , 14 – 24 ]. Figure 1 shows the study selection process.…”

Section: Resultsmentioning

confidence: 99%

“…Poor outcomes have been recently reported in patients with high SII values based on studies of other cancers, such as respiratory system cancers and digestive system cancers [ 7 , 8 , 11 ]. There is still a debate for the use of SII in urologic cancers, although an increasing number of studies has been performed on this topic, and the sample size in the existing research is not that large [ 12 , 13 ]. Therefore, we conducted a meta-analysis to investigate the prognostic role of SII in patients with urologic cancers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Huang

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Several studies have reported that the systemic immune-inflammation index (SII) is associated with the prognosis of patients with urologic cancers (UCs). The aim of this study was to systematically evaluate the prognostic value of SII in UC patients. Methods We searched public databases for relevant published studies on the prognostic value of SII in UC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled to assess the relationships between SII and overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), overall response rate (ORR) and disease control rate (DCR). Results A total of 14 studies with 3074 patients were included. From the pooled results, we found that high SII was associated with worse overall survival (OS) in patients with UC (HR 2.58, 95% CI 1.59–4.21). Patients with high SII values also had poorer PFS (HR 1.92, 95% CI 1.29–2.88) and CSS (HR 2.58, 95% CI 1.36–4.91) as well as lower ORRs (HR 0.40, 95% CI 0.22–0.71) than patients with low SII values. In addition, the subgroup analysis of OS and PFS showed that the prognosis of patients with high SII was worse than that of patients with low SII. Conclusions SII might be a promising noninvasive predictor in patients with UC. However, more samples and multicenter studies are needed to confirm the effectiveness of SII in predicting the prognosis of patients with UC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Huang

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported that peripheral blood cells, including neutrophils, lymphocytes, platelets, and monocytes, can promote tumor proliferation, invasion, and metastasis 12, 13. Thus, based on this evidence, many combinations of inflammatory indices such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and the systemic immune-inflammation index [(platelet × neutrophil)/ lymphocyte] have been used to predict the PCA prognosis 14-16. In parallel, the nutritional status of cancer patients also has been indicated as an important parameter affecting survival outcomes, including hemoglobin, albumin levels, and other nutrition indices 17-20.…”

Section: Introductionmentioning

confidence: 99%

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy

et al. 2019

View full text Add to dashboard Cite

Objective: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been shown to be an important prognostic marker in some tumor types. The aim of this study was to evaluate the prognostic impact of the preoperative HALP score, with the intent to develop a new prognostic index for patients with metastatic prostate cancer (mPCA) after cytoreductive radical prostatectomy (cRP).Methods: We retrospectively analyzed the data from 82 patients with mPCA after cRP in our institution. Of these patients, 70 patients were diagnosed with oligometastatic prostate cancer (oPCA). The main outcome measure was prostate-specific antigen (PSA) progression-free survival (PFS), which was assessed using Kaplan-Meier curves with log-rank statistics. In addition, univariate and multivariate Cox regression analyses were performed to determine the prognostic factors associated with PSA-PFS. The prediction accuracy was evaluated by assessing the area under the receiver operating characteristic (AUC) curve.Results: The median follow-up time for all patients was 17.47 months (range: 11.73-24.38 months). Based on the Kaplan-Meier curve analysis, it was noticed that a low preoperative HALP value (<32.4) was significantly associated with a decreased PSA-PFS in both the mPCA and oPCA subgroups (P < 0.001, P = 0.002, respectively). In addition, multivariate analysis predicted that a low HALP score was a common independent prognostic factor of an overall shorter PSA-PFS (HR: 0.352; range: 0.154-0.804; P = 0.013). However, among the different subgroups, a low HALP score (HR: 0.275; range: 0.116-0.653; P = 0.003) was confirmed to be an independent predictor of a shorter PSA-PFS in patients from the oPCA subgroup. Furthermore, the effective combination of the pathologic Gleason score (PGS) and the HALP score (HALPG) as a new index was found to be an independent risk factor. Also, the AUC of the HALPG score for PSA-PFS was observed to be higher than other conventional clinical indices.Conclusion: Overall, our results confirmed the HALP score as an independent prognostic factor for PSA-PFS in patients with mPCA or oPCA after cRP. Moreover, the new index, HALPG, also appeared to be an independent prognostic factor and was better than the HALP score. Importantly, it is evident that this new prognostic index has the ability to accurately identify patients at low, intermediate, and high risk of recurrence, thus easily allowing informed treatment decisions to be made.

show abstract

“…The NLR and PLR have been widely used to predict the prognosis in various cancers, [6][7][8][9][10][11] and the SII has recently been determined to be an independent prognostic factor in many kinds of cancers. [22][23][24][25][26][27][28][29] These inflammation-based indexes, however, have rarely been investigated simultaneously in HER2-positive breast cancer. To the best of our knowledge, the current study is the first to comprehensively investigate and compare the prognostic values of these inflammation-based indexes in Chinese population with HER2-positive breast cancer who received scheduled adjuvant trastuzumab.…”

Section: Discussionmentioning

confidence: 99%

“…21 The systemic immune-inflammation index (SII), which is a parameter integrates neutrophils, platelets and lymphocytes, has recently been assessed in various solid cancers: colorectal cancer, nasopharyngeal cancer, hepatocellular cancer, pancreatic cancer, gastric cancer and prostate cancer. [22][23][24][25][26][27][28][29] A recent study evaluated the prognostic significance of SII in hormone receptor (HR)-negative, HER2positive breast cancer, and showed that an increased SII independently predicted poor survival for HER2-positive breast cancer patients. 30 In this study, the median DFS rates of 15.1 and 31.5 months in high and low SII patients, respectively, indicated that the included patients were at an extremely high risk, as in the BCIRG006 trial, the 10-year DFS rate was as high as 75% in the general population.…”

Section: Introductionmentioning

confidence: 99%

<p>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab</p>

Jiang

Fang

Ding

2020

CMAR

View full text Add to dashboard Cite

Purpose: Neutrophils and platelets have been described as tumor-promoting factors, but lymphocytes have been described as tumor-inhibiting factors. The prognostic values of the neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been explored in human epidermal growth factor receptor (HER2)-positive breast cancer, however, the value of the systemic immune-inflammation index (SII) has not been studied in this molecular subtype. Our study aimed to compare the prognostic values of these inflammation-based indexes in Chinese HER2-positive breast cancer patients who received adjuvant trastuzumab. Methods: A total of 147 HER2-positive breast cancer patients were retrospectively analyzed. The association between clinicopathological factors and inflammation-based indexes was investigated. The Kaplan-Meier method was used to evaluate overall survival (OS) and disease-free survival (DFS); the Log rank test was performed to comparatively evaluate the survivals between the high-value and low-value groups. Multivariate Cox regression analysis was used to identify independent prognostic factors. Results: The SII value correlated significantly with histological grade (HG)(p=0.016). The cutoff values determined by ROC analysis for the NLR, PLR and SII were 1.69, 110 and 442, and the corresponding areas under the curves (AUCs) were 0.621, 0.639 and 0.674, respectively. The 5-year DFS was significantly lower in the NLR-high than in the NLR-low group (75.8% vs. 90.7%, p<0.01), in the PLR-high than in the PLR-low group (76.7% vs. 90.6%, p<0.01) and in the SII-high than in the SII-low group (66.8% vs. 90.7%, p<0.01). The 5-year OS was significantly lower in the PLR-high than in the PLR-low group (83.2% vs. 100%, p=0.035) and in the SII-high than in the SII-low group (77.3% vs. 96.4%, p=0.012). A multivariate regression model revealed that tumor size, lymph node involvement, HG, hormone receptor status, PLR and SII were independently correlated with DFS; lymph node involvement and SII were independently correlated with OS. Conclusion: Our study suggests that SII is an independent prognostic factor for DFS and OS in HER2-positive breast cancer, and in terms of prognostic reliability, the SII is superior to other inflammation-based indexes.

show abstract

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

Cited by 51 publications

References 36 publications

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy

<p>High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab</p>

Contact Info

Product

Resources

About